Cholesterol-lowering Drugs Help Reduce Mortality in Hospital Patients COVID-19: Study | Photo credit: iStock Images
- Large-scale study shows that statins often prescribed to help lower cholesterol can benefit COVID-19 inpatients
- Trial of 13,981 COVID-19 patients shows that statins help slow the progression of lung damage
- Researchers around the world are working around the clock to find a cure for the new coronavirus infection
Wuhan: New study suggests that statins used to lower cholesterol may help reduce the death rate in COVID-19 hospital patients. The development came when researchers at the University of Oxford discovered that dexamethasone, a cheap steroid, could be a life-saving drug for seriously ill COVID-19 patients in clinical trials.
The new study published in the journal Cell metabolism reported that common statins can improve immune cell responses, reduce inflammation, and slow the progression of lung damage in animal studies. However, the study indicated that it was not clear how the use of statins, alone or in combination with other drugs, would affect clinical outcomes in patients with COVID-19.
Without treatment or vaccine against SARS-CoV-2 infection, researchers from Renmin Hospital at Wuhan University conducted the study, involving 13,981 COVID-19 patients in 21 hospitals in the province from Hubei, Xinhua reported. Up to 1,219 patients received statins during the trial.
The researchers found that the death rate was 5.2% lower in the statin group compared to 9.4% in the non-statin group. This was observed after a follow-up 28 days later.
“These results have demonstrated the safety and efficacy of statins in the treatment of COVID-19 hospital patients,” said lead researcher Li Hongliang, who added that statins are promising drugs for COVID-19, especially when there is no vaccine or treatment approved for the disease.
In addition, the researchers also found that the use of statins was linked to a decrease in the incidence of invasive mechanical ventilation, admission to intensive care units and acute respiratory distress syndrome in COVID patients. -19.
For the study, 319 patients in the study received statins in combination with angiotensin converting enzyme inhibitors (ACEs) or angiotensin receptor inhibitors (ARBs), while 603 patients received taken statins with other high blood pressure medications. According to the study, adding an ACE inhibitor or an ARB did not increase the risk of death in these patients.
The large-scale study also stated that statins could help prevent COVID-19 patients from progressing to serious disease, as those taking statins had much lower levels of inflammation biomarkers. than those who were not using cholesterol-lowering drugs.